[Clinical administration of BCG-immunotherapy in malignant melanoma (author's transl)].
In the Department of Dermatology of the University of Jena 60 patients with malignant melanoma received the immunotherapy by means of the BCG high-dosis scarification method after maximum surgical removal of the tumour. The results after 3 years of treatment demonstrate that the BCG strain Jena can cause immunostimulation. Rates of remission and survival could be well influenced. No serious side effects were observed.
D001500:BCG Vaccine / Q000627:therapeutic use*; D006801:Humans; D008545:Melanoma / Q000601:surgery / Q000628:therapy*; D012878:Skin Neoplasms / Q000601:surgery / Q000628:therapy*
D001500:BCG Vaccine
Klinische Anwendung der BCG-Immuntherapie beim malignen Melanom.